Potential diagnostic and prognostic marker dimethylglycine dehydrogenase (DMGDH) suppresses hepatocellular carcinoma metastasis in vitro and in vivo

Oncotarget

Volumn 7, Issue 22, 2016, Pages 32607-32616

  Liu, Gang ^a   Hou, Guojun ^b   Li, Liang ^b   Li, Yixue ^a   Zhou, Weiping ^b   Liu, Lei ^c  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Diagnosis; DMGDH; Hepatocellular carcinoma; Metastasis; Prognosis

Indexed keywords

DIMETHYLGLYCINE DEHYDROGENASE; PROTEIN KINASE B; RNA; DMGDH PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER PROGNOSIS; CANCER TISSUE; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MICROARRAY ANALYSIS; MIGRATION INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; SIGNAL TRANSDUCTION; TUMOR INVASION; WESTERN BLOTTING; CELL PROLIFERATION; ENZYMOLOGY; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SURVIVAL RATE;

BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DIMETHYLGLYCINE DEHYDROGENASE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; MITOCHONDRIAL PROTEINS; PROGNOSIS; SURVIVAL RATE;

EID: 84973558177     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8927     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA-Cancer J Clin. 2005; 55:74-108.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132:2557-2576.
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009; 27:1485-1491.
4. Huang Q, Tan Y, Yin P, Ye G, Gao P, Lu X, Wang H, Xu G. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res. 2013; 73:4992-5002.
5. Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T, Gonzalez FJ, Dufour JF, Idle JR. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res. 2011; 71:6590-6600.
6. Villanueva A, Llovet JM. Liver cancer in 2013: Mutational landscape of HCC-the end of the beginning. Nat Rev Clin Oncol. 2014; 11:73.
7. Wu S, Le H. Dual roles of PKM2 in cancer metabolism. Acta Bioch Bioph Sin. 2013; 45:27-35.
8. Juan L, Cen Z, Meihua L, Wei Z, Yingjian L, Xuehui H, Yuhan Z, Young KH, Wenwei H, Zhaohui F. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget. 2014; 5:2635-2647. doi: 10.18632/oncotarget.1862.
9. Bansal S, Berk M, Alkhouri N, Partrick DA, Fung JJ, Feldstein A. Stearoyl-CoA desaturase plays an important role in proliferation and chemoresistance in human hepatocellular carcinoma. J Surg Res. 2014; 186:29-38.
10. Skill NJ, Scott RE, Wu J, Maluccio MA. Hepatocellular carcinoma associated lipid metabolism reprogramming. J Surg Res. 2011; 169:51-56.
11. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, Chen WW, Barrett FG, Stransky N, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011; 476:346-350.
12. Takigawa Y, Brown AM. Wnt signaling in liver cancer. Current drug targets. 2008; 9:1013.
13. Yang CC, Chang SF, Chao JK, Lai YL, Chang WE, Hsu WH, Kuo WH. Activation of AMP-activated protein kinase attenuates hepatocellular carcinoma cell adhesion stimulated by adipokine resistin. Bmc Cancer. 2014; 14:112.
14. Feng D, Zheng H, Tan Y, Cheng R. Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. World J Gastroentero. 2001; 7:33-36.
15. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. Faseb J. 2004; 18:1123-1125.
16. Chen Js, Wang Q, Fu Xh, Huang XH, Chen Xl, Cao Lq, Chen Lz, Tan Hx, Li W, Bi J. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res. 2009; 39:177-186.
17. Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, Izzo F, La Vecchia C, Boffetta P, Montella M. Metabolic syndrome and hepatocellular carcinoma risk. Brit J Cancer. 2013; 108:222-228.
18. Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KT, Ibdah JA. Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol. 2013; 5:186-194.
19. Steelman LS, Chappell WH, Abrams SL, Kempf CR, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging. 2011; 3:192.
20. Sheng S, Qiao M, Pardee AB. Metastasis and AKT activation. J Cell Physiol. 2009; 218:451-454.
21. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC. Dual regulation of Snail by GSK-3ß-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004; 6:931-940.
22. Karolchik D, Barber GP, Casper J, Clawson H, Cline MS, Diekhans M, Dreszer TR, Fujita PA, Guruvadoo L, Haeussler M, Harte RA, Heitner S, Hinrichs AS, et al. The UCSC Genome Browser database: 2014 update. Nucleic Acids Res. 2014; 42:D764-770.
23. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009; 25:1105-1111.
24. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012; 7:562-578.
25. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing S. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25:2078-2079.
26. Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER, Weinstock GM, Wilson RK, Ding L. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics. 2009; 25:2283-2285.
27. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38:e164.